TRIP13 and plasma cell myeloma: Our proteomic analyses in multiple myeloma cell lines revealed that CDK6 governs many of the proteins deregulated at relapsed/resistant disease, either through direct phosphorylation of proteins or by indirect alterations of the transcriptional activity of genes including TRIP13 and RRM1, and is thus a master regulator of a relapse-associated program.